# Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer

> **NCT00334763** · PHASE2 · TERMINATED · sponsor: **Northwestern University** · enrollment: 32 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** carboplatin
- **DRUG:** chemoprotection
- **DRUG:** paclitaxel
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00334763
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05
- **Primary completion:** 2007-05
- **Final completion:** 2007-11
- **Target enrollment:** 32 (ESTIMATED)
- **Why stopped:** Principal Investigator felt risk to patients was too high.
- **Last updated:** 2012-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00334763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00334763, "Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00334763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*